Kyntra Bio Inc (KYNB) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access KYNB Annual Income Statement →
This income statement overview for Kyntra Bio Inc spans from Mar 31 2025 to Mar 31 2026, showing how the company's revenues, expenses, and earnings have changed across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
Q1 2026
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Revenues
Revenue From Contract With Customer Excluding Assessed Tax3.74
Total Revenue3.74
Costs & Expenses
Cost of Goods and Services Sold4.11
Gross Profit-0.37
Selling, Administration, Marketing5.86
Depreciation & Amortization0.00
Research and Development Expense7.57
Restructuring Charges0.02
Other Operating Expense / -Income0.00
Total operating costs including COS17.56
Operating income / -loss-13.82
Interest Expense2.43
Interest Expense, Borrowings0.00
Net Interest Expense / -Income1.31
Extinguishment of Debt0.00
Other loss / -income0.00
Total costs & expenses18.87
Income & Taxes
Income / -loss before income taxes-15.13
Income taxes expenses / -benefit0.00
Income after income taxes-15.13
Net income / -loss of other equity0.00
Income / -loss from continuing operations-15.13
Discontinued operations-0.07
Net income / -loss-15.20
Income / -loss to shareholder-15.20
EBIT-13.82
EBITD-13.82
EBITDA-13.82
Earnings Per Share
Basic EPS (excl. extra items)-3.74
Extraordinary items-0.02
Basic Net EPS-3.76
Basic shares outstanding (Mill. of Units)4.05
Diluted Net EPS-3.76
Diluted average shares (Mill. of Units)4.05
4 historic quarters locked

Sign in to unlock the full Kyntra Bio Inc income statement history.

About Kyntra Bio Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: August 13, 2026
  • Original filing: kynb-20260630.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.